Evidence map›Paper›PMID 20394539›Full record

ReviewNanomedicine (London, England)2010

Nanomicellar formulations for sustained drug delivery: strategies and underlying principles.

Ruchit Trivedi, Uday B Kompella

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomedicine (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed.

  1. TetronicPharmaceutics · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Overview of Recent Advances in Nano-Based Ocular Drug Delivery.International journal of molecular sciences · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ruchit TrivediDepartment of Pharmaceutical Sciences, University of Colorado Denver, 12700 E 19th Avenue, C238-P15, Aurora, CO 80045, USA.
Uday B Kompella

Funding

Transscleral Drug Delivery for Retinal DisordersR24EY017045 · NEI · EMORY UNIVERSITY · PI EDELHAUSER, HENRY FRANCIS · 2006 to 2010
$6.9M
Development of Small Heat Shock Proteins as Therapeutic Agents in the EyeRC1EY020361 · NEI · UNIVERSITY OF COLORADO DENVER · PI PETRASH, JONATHAN MARK · 2009 to 2010
$992k
NEI NIH HHS R24 EY017045NEI NIH HHS RC1 EY020361
6 · The paper itself

Abstract

Micellar delivery systems smaller than 100 nm can be readily prepared. While micelles allow a great depth of tissue penetration for targeted drug delivery, they usually disintegrate rapidly in the body. Thus, sustained drug delivery from micellar nanocarriers is a challenge. This article summarizes various key strategies and underlying principles for sustained drug delivery using micellar nanocarriers. Comparisons are made with other competing delivery systems such as polymeric microparticles and nanoparticles. Amphiphilic molecules self-assemble in appropriate liquid media to form nanoscale micelles. Strategies for sustained release nanomicellar carriers include use of prodrugs, drug polymer conjugates, novel polymers with low critical micellar concentration or of a reverse thermoresponsive nature, reverse micelles, multi-layer micelles with layer by layer assembly, polymeric films capable of forming micelles in vivo and micelle coats on a solid support. These new micellar systems are promising for sustained drug delivery.

Indexed as

MicellesAnimalsDrug Delivery SystemsHumansNanostructuresNanotechnologyMicelles

Identifiers

PMID20394539
PMCPMC2902878

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.